Medical Device Global Market Access

This episode provides a detailed overview of Brazil's pivotal medical device regulation, ANVISA RDC 751/2022, which became effective in March 2023. We explore its comprehensive framework, including the four-tier risk classification system, the distinct pathways for notification and registration, and its alignment with international standards like the IMDRF Table of Contents. The host also discusses modernized rules for Software as a Medical Device (SaMD) and what these significant changes mean for manufacturers seeking market access in Brazil. - What is ANVISA's RDC 751/2022 and why is it critical for device manufacturers? - How does Brazil classify medical devices by risk under the new regulation? - What is the difference between the 'notificação' and 'registro' pathways? - How does RDC 751/2022 align with global standards like the IMDRF? - Are there new rules for Software as a Medical Device (SaMD) in Brazil? - What previous regulations did RDC 751/2022 replace? - When did this new regulation become effective? - How can manufacturers leverage their existing technical files for Brazilian submission? Pure Global simplifies the complexities of global market access for MedTech and IVD companies. Our experts in Brazil provide end-to-end support for ANVISA registration under RDC 751/2022, from developing a regulatory strategy and compiling technical dossiers to acting as your official in-country representative. By leveraging advanced AI and a deep understanding of local requirements, we help you achieve faster, more efficient market entry. Let us manage the regulatory hurdles so you can focus on innovation. Contact us at [email protected], visit https://pureglobal.com, or explore our FREE AI tools and database at https://pureglobal.ai.

This episode delves into the critical process for medical device manufacturers to regain control of their Singapore market access by transitioning from a distributor-held registration to an independent registrant. We explain why tying your regulatory license to a commercial partner creates business risks and outline the strategic advantages and procedural steps involved in making the switch with Singapore's Health Sciences Authority (HSA). Key Questions: • What is an HSA Registrant and why is it mandatory for selling medical devices in Singapore? • Are you unknowingly locked in with your current Singaporean distributor? • What happens to your product license if you terminate your distributor agreement? • How does appointing an independent representative give you full control over your market access? • What is the official process for changing your Local Authorized Representative with the HSA? • Why can't you simply "transfer" your existing medical device registration to a new entity? • What key document do you need to authorize a new independent registrant? • How does this change impact your ability to work with multiple distributors? • What are the long-term benefits of separating your regulatory and commercial partners? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode delves into the critical process of changing a medical device registration holder in Vietnam. We clarify a common misconception: a direct license transfer between holders is not permitted by the Ministry of Health. Instead, manufacturers must navigate a full re-registration process. We outline the steps involved and highlight the significant strategic advantages of appointing an independent registration holder to maintain control and flexibility over your market access. Key Questions: • Thinking of changing your distributor in Vietnam? • Is your medical device registration currently held by your commercial partner? • What happens to your market access if that partnership ends? • Can you simply transfer a device registration from a distributor to a new company in Vietnam? • What is the official process for changing your registration holder with the MOH? • Why is appointing an independent registration holder a smarter long-term strategy? • How can you avoid being locked into an underperforming distributor? • What are the risks of a distributor refusing to cancel an existing registration? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode explores the critical strategic choice between appointing a distributor versus an independent Designated Marketing Authorization Holder (D-MAH) for medical device registration in Japan. We break down how using an independent D-MAH allows foreign manufacturers to retain ownership of their marketing approvals, providing essential flexibility in distribution strategy, safeguarding confidential information, and ensuring robust regulatory compliance in the Japanese market. Key Questions: • What is the difference between an MAH and a D-MAH in Japan? • Who legally owns your product registration if your distributor is the MAH? • What happens to your market access if you want to switch distributors in Japan? • How can you protect your confidential device information from your commercial partners? • Why is an independent D-MAH a more flexible long-term strategy? • What is the Foreign Special Approval System (FSAS) and how does it help foreign manufacturers? • How does using an independent D-MAH impact your commercial and distribution strategy? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode delves into the strategic process of changing a TGA Sponsor for medical devices in Australia. We explore the critical differences between using a distributor as a sponsor versus an independent sponsor, outlining the risks of the former and the long-term benefits of the latter. Learn about the official transfer process, the importance of Manufacturer Evidence, and the key steps to ensure a smooth transition while maintaining market access and regulatory control. Key Questions: • What is the role of a TGA Sponsor in Australia? • Why is using your distributor as a sponsor a potential risk to your business? • How does an independent sponsor give you more control over your market strategy? • What is the official process for transferring a medical device registration to a new sponsor? • What is "Manufacturer Evidence" and why is it crucial for a sponsor transfer? • Are there any TGA fees associated with changing sponsors? • How can you ensure a seamless handover of regulatory responsibilities? • What should be included in a transfer agreement between sponsors? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode explores the critical process of switching your Indian Authorized Agent (IAA) with the CDSCO, moving from a commercially-tied distributor to an independent regulatory partner. We detail the significant business risks of using a distributor as your agent and provide a step-by-step guide for making the change, including the crucial role of the No-Objection Certificate (NOC). Learn how an independent IAA provides commercial flexibility and secures your long-term market access in India. Key Questions: • What are the primary responsibilities of an Indian Authorized Agent (IAA)? • Why is it risky to appoint your distributor as your legal representative in India? • What is a No-Objection Certificate (NOC) and why is it essential for changing your IAA? • Is it possible to transfer an existing CDSCO import license to a new agent? • What is the official process for appointing a new independent IAA with the CDSCO? • How does an independent IAA grant you more control over your commercial strategy? • What documents are required to prove no changes have been made to the device during the switch? • How can this change protect your business from being held hostage by a commercial partner? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode delves into the critical process of transferring ANMAT medical device registration in Argentina from a distributor to an independent holder. We explore the strategic risks of distributor-held registrations, such as commercial lock-in, and provide a clear overview of the transfer process, including the role of the Argentina Authorized Representative (AAR) and the importance of the governing regulation, ANMAT Provision 9688 of 2019. Listeners will learn the necessary steps and key considerations for regaining control of their market access. Key Questions: • Why is letting your distributor own your device registration a major risk in Argentina? • What is an Argentina Authorized Representative (AAR) and how do they provide market flexibility? • Which key ANMAT regulation governs the transfer of registration ownership? • What is the most critical step for ensuring a smooth transfer from your current distributor? • How long does the official ANMAT review process for a registration transfer take? • What crucial clause should be included in all your distributor agreements to protect your registration? • Can you force a distributor to transfer your registration if they refuse? • What are the long-term commercial benefits of using an independent registration holder? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode explores a crucial, often overlooked aspect of entering the Chilean medical device market: the selection of an in-country registration holder. We detail the significant risks of appointing a distributor as your registration holder with the Instituto de Salud Pública (ISP), including loss of market control and conflicts of interest. The discussion then shifts to the strategic advantages of using an independent, third-party representative, which ensures manufacturers retain full ownership and flexibility over their product registrations and commercial strategy. • Why is choosing your registration holder in Chile a critical strategic decision? • What are the hidden risks of letting your distributor own your product registration? • How can a distributor legally hold your market access hostage? • What is the primary conflict of interest when a distributor manages your regulatory compliance? • How does appointing an independent holder give you complete control over your commercial strategy? • What is the role of the Instituto de Salud Pública (ISP) in medical device registration? • Can you switch distributors easily if they are your registration holder? • How does an independent holder model protect your company's long-term interests? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode explores the critical risks of allowing a distributor to hold your medical device registration in Peru and outlines the strategic advantages of using an independent Peru Registration Holder (PRH). We discuss how this decision impacts your market control, business flexibility, and long-term security. Learn about the process of transferring registration ownership with DIGEMID and why separating your regulatory representation from your commercial partnerships is essential for success. • What is a Peru Registration Holder (PRH) and why is it mandatory? • Are you putting your market access at risk by letting your distributor hold your DIGEMID registration? • What happens to your device registration if you change distributors in Peru? • How does an independent registration holder give you more control and flexibility? • What is the process for transferring registration ownership from a distributor to an independent holder? • Which key regulations, like Decree No. D.S. 029-2015-SA, govern this change? • Why is selecting the right PRH a critical strategic decision for long-term success in Peru? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode explores the critical process of transferring a medical device registration holder in Mexico. We uncover the risks of appointing a distributor as your legal representative with COFEPRIS and detail the complex legal steps required for a transfer of rights. Learn why choosing an independent registration holder from the outset is the key to maintaining control over your market access and commercial flexibility in this major Latin American market. Key Questions: • What is a Mexico Registration Holder (MRH) and why are they legally significant? • What are the hidden dangers of letting your distributor own your COFEPRIS registration? • Can you be locked out of the Mexican market by a former distributor? • What is the official "transfer of rights" process for a medical device registration? • What legal documents and cooperation are required from the original registration holder? • Why might a distributor refuse to transfer your registration? • What is the costly alternative to a smooth registration transfer? • How does appointing an independent holder protect your business interests? • Why is separating regulatory ownership from commercial distribution a vital strategy? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode explores the critical decision of who holds your INVIMA medical device registration in Colombia. We delve into the significant business risks of allowing a distributor to be the registration holder and outline the strategic advantages of using an independent third party. Learn about the process for transferring ownership, the potential pitfalls of an uncooperative distributor, and how to maintain full control over your commercial strategy in this key Latin American market. • What is an INVIMA Registration Holder and why does it critically impact your business? • Are you exposing your company to risk by letting your distributor control your market access? • How does an independent registration holder provide commercial flexibility? • What is the official process for switching your registration holder in Colombia? • What happens if your current distributor refuses to transfer the registration? • Can you work with multiple distributors under a single registration? • How can you avoid being locked into a single commercial partner? • What is the best practice for new companies entering the Colombian market? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode delves into a crucial aspect of the Brazilian medical device market: the role of the Brazil Registration Holder (BRH). We explore the significant differences and long-term consequences of appointing a distributor versus an independent third party to hold your device registration with ANVISA. Learn how to avoid common pitfalls that can limit your commercial flexibility and gain control over your market strategy. • What is a Brazil Registration Holder (BRH) and why is it mandatory? • What are the hidden risks of appointing your distributor as your BRH? • How does using a distributor as a BRH limit your ability to change sales partners? • Why is an independent BRH a more strategic choice for market entry? • What are the benefits of separating regulatory holding from commercial distribution? • What does Brazilian Resolution RDC 102/2016 say about transferring a registration? • How can you protect your intellectual property when registering a device in Brazil? • What is the best strategy to ensure long-term control and flexibility in the Brazilian market? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode explores the pivotal regulatory change in the United Arab Emirates allowing medical device manufacturers to appoint an independent Local Authorized Representative (LAR), decoupling registration from commercial distribution. We analyze the risks of the old distributor-as-LAR model and highlight the strategic advantages of the new system, including enhanced market flexibility, greater control over registrations, and improved business continuity for MedTech companies targeting the UAE. • Why was appointing a distributor as your LAR in the UAE a major business risk? • What specific change did the UAE's Ministry of Health and Prevention (MOHAP) implement regarding in-country representation? • How does an independent LAR give manufacturers more control over their products? • What are the key strategic benefits of separating regulatory compliance from commercial sales? • Can you appoint multiple distributors in the UAE after this change without re-registering your device? • What are the core responsibilities of an independent LAR? • How does this shift affect your ability to enter or scale within the UAE market? • Does the manufacturer or the LAR own the device registration under the new model? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode unpacks a crucial change in Turkey's medical device regulations following its alignment with the EU MDR on June 2, 2021. We explore why foreign manufacturers can no longer use their commercial distributors as their Turkish Authorized Representative (TR-REP). The discussion focuses on the inherent conflict of interest between sales and regulatory compliance, the legal responsibilities of an independent TR-REP, and the necessary steps manufacturers must take to appoint a new representative and update their registrations in the ÜTS database to maintain market access. Key Questions: • Why is using your distributor as your Turkish Authorized Representative (TR-REP) now a significant compliance risk? • What is the fundamental conflict of interest between a distributor's commercial goals and a representative's regulatory duties? • How did Turkey's alignment with the EU MDR on June 2, 2021, fundamentally change the role of the TR-REP? • What are the specific legal responsibilities of an independent TR-REP? • What are the essential steps to transition from a distributor-rep to an independent TR-REP? • How does this regulatory shift affect your device registrations in the Turkish ÜTS database? • What are the potential consequences of failing to appoint an independent TR-REP in Turkey? • Does an independent TR-REP model improve patient safety and post-market surveillance? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode explores the critical strategic decision for medical device manufacturers in Saudi Arabia: moving from a distributor-based Local Authorized Representative (LAR) to an independent one. We delve into the significant risks of tying your SFDA product registrations to a commercial partner and outline the clear benefits and straightforward process for making the switch. Learn how to take control of your market access, enhance your strategic flexibility, and secure your business in the Kingdom. • What are the hidden risks of appointing your Saudi distributor as your regulatory representative? • How can a distributor-LAR relationship hold your market access hostage? • What are the strategic advantages of using an independent, third-party LAR? • Is it difficult to switch from a distributor to an independent LAR in Saudi Arabia? • Do you need your current distributor’s permission to make the change? • Will you lose your existing product registrations (MDMA) if you switch representatives? • What does the SFDA require for a smooth transfer process? • Why is this topic more important than ever for low-risk devices since September 2022? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode delves into the critical role of the Swiss Authorized Representative (CH-REP) for medical device manufacturers. We explore the significant regulatory changes that made the CH-REP mandatory and uncover the hidden risks of appointing a commercial distributor for this function. Learn why an independent CH-REP is the more strategic choice for ensuring long-term compliance and commercial flexibility in the Swiss market. • Why did Switzerland become a regulatory "third country" for medical devices on May 26, 2021? • What are the core duties and legal liabilities of a Swiss Authorized Representative (CH-REP)? • What is the fundamental conflict of interest when your distributor is also your CH-REP? • How does tying regulatory compliance to a sales partner limit your commercial freedom? • Is your distributor truly equipped to handle joint liability for your devices? • What makes an independent CH-REP a more robust and flexible long-term solution? • What is involved in the process of switching from a distributor to an independent CH-REP? • Are there still grace periods for appointing a Swiss representative? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode explores the critical shift for medical device manufacturers from using a distributor as their EU Authorized Representative (EC-REP) to appointing a professional, independent representative in France. We delve into the increased liabilities under the MDR, the inherent conflicts of interest in the distributor model, and the significant commercial and regulatory advantages of partnering with an independent AR for streamlined access to the French and broader EU markets. • Why is using a distributor as your EU Authorized Representative now considered a major risk? • What specific liabilities did the EU MDR place on Authorized Representatives? • How does an independent EC-REP provide greater market flexibility in France and across the EU? • What is the fundamental conflict of interest between a distributor's goals and an AR's duties? • What are the key steps involved in switching from a distributor to an independent AR? • How does this change affect your product labeling and registration? • Why is a formal transfer agreement essential for a smooth transition? • How can an independent AR improve your relationship with competent authorities like France's ANSM? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode details the strategic process for medical device manufacturers to transition from a distributor-based EU Authorized Representative (EC-REP) to an independent one in Germany. We cover the regulatory requirements under MDR Article 12, the importance of the tripartite agreement, and the necessary steps for a smooth handover, including German database updates and labeling changes. • Why is using a distributor as an EC-REP a potential conflict of interest? • What is the first step in terminating an agreement with a distributor-representative? • What is a tripartite agreement and why is it essential for this change? • Which specific details must be included in the handover agreement? • How are post-market surveillance duties handled for devices already on the market? • Which German authority and database are involved in this process? • What are the practical implications for product labeling and packaging? • Do you need to inform your Notified Body about the change in EC-REP? • What are the key benefits of using an independent EC-REP? • How does an independent EC-REP better protect a manufacturer's intellectual property? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

Since Brexit, non-UK medical device manufacturers need a UK Responsible Person (UKRP) to access the Great Britain market. While appointing a local distributor for this role is a common shortcut, it creates a significant conflict of interest between sales and regulatory compliance. This episode explores the hidden risks of this approach—from a lack of regulatory expertise to giving a commercial partner leverage over your market access—and makes the case for appointing a specialized, independent UKRP for long-term business security and continuity. • What is the UK Responsible Person (UKRP) and why is it mandatory after Brexit? • Why is appointing a distributor as your UKRP a potential conflict of interest? • How could a distributor's sales focus compromise your regulatory compliance? • Does your distributor possess the necessary expertise to engage with the MHRA? • What happens to your market access if you end your agreement with a distributor who is also your UKRP? • How does using a distributor as your UKRP risk your confidential technical files? • What are the key advantages of appointing a dedicated, independent UKRP? • How does separating regulatory and commercial functions provide business flexibility? • Is your current UKRP strategy built for long-term success or short-term convenience? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode explores the critical need for non-EU medical device manufacturers to replace their distributor-based EU Authorized Representative (EC-REP) with an independent one, particularly for the Spanish market. We delve into the increased liabilities for EC-REPs under the EU MDR (Regulation (EU) 2017/745), the inherent conflicts of interest when a distributor holds this role, and the clear benefits of partnering with a neutral, compliance-focused representative. Learn the official step-by-step process for making this crucial transition to secure your market access and protect your intellectual property. Key Questions: • Why is using your Spanish distributor as your EU Authorized Representative a major risk under the new MDR? • What specific liabilities does your EC-REP now share with you for defective devices? • How does an independent representative protect your confidential technical documentation from competitors? • What is the official process for changing your EC-REP in Spain? • How does the tripartite agreement work between the manufacturer, the old rep, and the new one? • What are the critical labeling changes you must make when you switch representatives? • Could a conflict of interest with your distributor-rep jeopardize your market access? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode explores the critical shift for MedTech manufacturers from using distributors to appointing independent Authorized Representatives (EC-REPs) in Italy, driven by the EU's Medical Device Regulation (MDR). We unpack the increased legal liabilities, conflicts of interest, and commercial risks associated with the old model, and explain why an independent AR is now essential for secure and flexible market access. Key Questions: • Why is using your Italian distributor as your EU Authorized Representative a major risk under the new MDR? • What does "jointly and severally liable" mean for your European regulatory partner? • How does the EU MDR create a conflict of interest for a distributor acting as your AR? • Can your distributor legally hold your device registrations hostage if you want to switch partners? • What are the strategic advantages of appointing an independent EC-REP for the Italian market? • How does separating your regulatory and commercial partners improve your business flexibility? • What is the primary role of an Authorized Representative in communicating with the Italian Ministry of Health? • Does your current EU AR agreement protect you from the new liability clauses in Regulation (EU) 2017/745? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode delves into the crucial role of the Pemegang Izin Edar, or Local Authorized Representative, for medical device market access in Indonesia. We explore the regulatory requirements mandated by the Ministry of Health, the responsibilities of the license holder, and the critical strategic differences between appointing a distributor versus an independent third party to hold your product registration. Understanding this choice is fundamental to maintaining control and flexibility in this key Southeast Asian market. Key Questions: • What is a "Pemegang Izin Edar" and why is it mandatory for foreign manufacturers in Indonesia? • Who is legally responsible for a medical device on the Indonesian market? • What are the main responsibilities of a Local Authorized Representative? • Should you appoint your distributor as your product license holder? • What are the risks of tying your device registration to a single commercial partner? • How can an independent license holder provide greater market flexibility and control? • What happens if you need to change your local representative in Indonesia? • Which key regulation, established in 2017, governs medical device distribution licenses? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode delves into the essential requirement for medical device manufacturers to appoint a Marketing Authorization Holder (MAH) or Local Authorized Representative to enter the United Arab Emirates market. We explore the role and responsibilities of this local partner as mandated by the Ministry of Health and Prevention (MOHAP), the strategic implications of choosing a distributor versus an independent representative, and the key functions they perform in device registration and post-market surveillance. • What is a Marketing Authorization Holder in the UAE? • Why is appointing a local representative mandatory for foreign medical device manufacturers? • What are the core responsibilities of a UAE-based authorized representative? • Should you appoint your distributor or an independent third party as your local agent? • How does this choice impact your long-term market strategy and flexibility? • What key documentation is managed by the local representative during registration with MOHAP? • How long is a typical medical device registration valid in the UAE? • What role does the representative play in post-market surveillance and vigilance? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode provides a detailed overview of the mandatory requirement for medical device manufacturers to appoint a Saudi Authorized Representative (AR) to enter the market in Saudi Arabia. We explore the key responsibilities of the AR, from regulatory submissions with the Saudi Food and Drug Authority (SFDA) to post-market surveillance, and analyze the strategic advantages of appointing an independent AR over a commercial distributor. Key Questions • What is a Saudi Authorized Representative and why is it mandatory for foreign manufacturers? • What are the essential duties an AR performs on behalf of a medical device company? • What are the benefits of choosing an independent AR versus appointing your distributor? • How did the regulations for low-risk medical devices change on September 27, 2022? • What qualifications must a local entity possess to become an SFDA-approved AR? • What is the process for submitting a Medical Device Marketing Authorization (MDMA) via an AR? • Can a manufacturer change their appointed AR without re-registering their products? • What legal documentation is required to formalize the relationship with a Saudi AR? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode delves into the essential role of the Marketing Authorization Holder (MAH) for medical device registration in the Philippines. We explore the regulatory requirements set by the Philippine FDA, the responsibilities of an MAH, and the critical strategic considerations for foreign manufacturers when selecting a local representative. Understanding the distinction between a distributor-as-MAH and an independent MAH is key to maintaining control over your market access and long-term business flexibility. Key Questions: • What is a Marketing Authorization Holder (MAH) and why is it mandatory in the Philippines? • Who is eligible to act as an MAH for medical devices? • What are the legal responsibilities of the MAH after a product is on the market? • Is it a good idea to appoint your distributor as your MAH? • How can your choice of MAH impact your business control and market flexibility? • What is a Certificate of Product Registration (CPR) and why is its ownership so important? • What happens to your device registration if you decide to switch distributors? • How does an independent MAH provide a more secure path to market? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

Navigating the Israeli medical device market requires a deep understanding of its unique regulatory landscape. This episode provides a comprehensive overview of the Israel Registration Holder (IRH), a mandatory in-country representative for foreign manufacturers. We explore the IRH's crucial role in liaising with the AMAR (Ministry of Health), their extensive responsibilities from registration to post-market surveillance, and the strategic advantages of appointing an independent holder over a distributor. We also touch on the 2024 regulatory reforms that have streamlined market access. • What is an Israel Registration Holder (IRH) and why is it mandatory? • Who is the regulatory authority for medical devices in Israel? • What are the core responsibilities of an IRH? • Should you appoint your distributor as your IRH? • What are the risks of tying your registration to a commercial partner? • How does an independent IRH protect your intellectual property and market control? • What key qualifications must an IRH possess, such as ISO 9001 certification? • How have the 2024 registration reforms impacted market entry strategy? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode delves into the essential role of the License Holder (ผู้รับใบอนุญาต) for foreign medical device manufacturers entering the Thai market. We explain why appointing a local representative is mandatory under the Medical Devices Act, detailing their key responsibilities which include obtaining an Establishment License, managing product registration with the Thai FDA, and overseeing all post-market surveillance and vigilance activities. We also analyze the critical strategic decision between appointing a distributor versus an independent third-party representative and the long-term commercial implications of that choice. Key Questions • What is a License Holder and why is one mandatory for selling medical devices in Thailand? • Which Thai regulations govern the role of an in-country representative? • What are the primary legal duties of a Local Authorized Representative, from pre-market to post-market? • Should you appoint your distributor as your official License Holder? • What are the commercial risks of tying your product registration to a single distribution partner? • How can an independent representative provide greater control and market flexibility? • What is an Establishment License and how does it relate to product registration? • Who is responsible for vigilance and adverse event reporting to the Thai FDA? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode delves into the essential roles of the Authorized Representative (AR) and Registrant for medical device market access in Malaysia. We clarify the legal requirements under the Medical Device Act 2012 (Act 737), explain the responsibilities of a Malaysian AR, and break down the critical strategic differences between appointing a distributor versus an independent third-party as your representative. Understanding this distinction is key to maintaining control over your device registration and ensuring long-term market flexibility. Key Questions: • What is a Malaysia Authorized Representative (AR)? • Who is considered the "Registrant" for a medical device in Malaysia? • What are the legal responsibilities of an AR according to the Medical Device Act 737? • Why is it risky to appoint a distributor as your Authorized Representative? • How does using an independent AR give manufacturers more control? • What qualifications must an entity have to act as an AR in Malaysia? • Can a manufacturer have more than one AR? • What is the MeDC@St system and who uses it? • How does the AR handle post-market surveillance and vigilance? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode provides a detailed overview of the mandatory Registration Number Holder (Tổ chức đứng tên đăng ký) in Vietnam for foreign medical device manufacturers. We explore the critical legal, post-market, and commercial responsibilities assigned to this local entity under the governing regulation, Decree 98/2021/ND-CP, which came into effect on January 1, 2022. Key obligations discussed include post-market surveillance, adverse event reporting, product recalls, price declaration, advertising compliance, and warranty provision. Key Questions: • What is a Registration Number Holder and why is it essential for selling medical devices in Vietnam? • Which key Vietnamese regulation defines the responsibilities of the Registration Number Holder? • What are the holder's primary duties regarding post-market surveillance and traceability? • Who is legally responsible for managing adverse events and product recalls in the Vietnamese market? • How is the price of a medical device controlled and declared to the Ministry of Health? • What are the rules for advertising medical devices in Vietnam? • What are the warranty and service obligations of the Registration Number Holder? • How does the choice of a Registration Number Holder impact a manufacturer's compliance and success? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode demystifies the single most critical requirement for medical device manufacturers entering the Singaporean market: the local Registrant. We explore the legal framework established by the Health Products Act of 2007, defining the Registrant's non-negotiable role as the in-country representative responsible for product registration, post-market surveillance, and all communication with the Health Sciences Authority (HSA). Listeners will learn about the Registrant's key responsibilities and the strategic implications of choosing between a distributor and an independent third-party representative. Key Questions: • What is the Singapore Health Products Act and how does it affect foreign medical device companies? • Why can't overseas manufacturers register their devices directly with the HSA? • Who is legally qualified to act as a medical device Registrant in Singapore? • What are the core responsibilities of a Registrant, from initial submission to post-market reporting? • How does the Registrant handle adverse events and Field Safety Corrective Actions (FSCAs)? • What is the strategic difference between appointing a distributor versus an independent firm as your Registrant? • How can your choice of Registrant impact your long-term business flexibility and market control? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode breaks down the essential role of the Authorized Indian Agent (AIA) for medical device companies entering the Indian market. We explore the regulatory framework under the CDSCO, the specifics of the MD-14 and MD-15 forms, and the critical strategic considerations when appointing your in-country representative. • What is an Authorized Indian Agent (AIA) and why is it mandatory in India? • How do Forms MD-14 and MD-15 govern the medical device import license process? • What are the key responsibilities of an AIA beyond the initial registration? • Can a distributor act as an Authorized Indian Agent? • What are the risks of tying your import license to a single commercial partner? • Why is the MD-15 license non-transferable, and what does this mean for your business? • How can you maintain commercial flexibility with multiple distributors? • What qualifications must an entity have to become an AIA? • What is the role of the CDSCO's Medical Device Rules, 2017, in this process? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode demystifies the mandatory role of the In-China Domestic Agent for foreign medical device manufacturers entering the Chinese market. We explore the legal basis under State Council Order 739, effective June 1, 2021, and detail the agent's critical responsibilities in registration, NMPA communication, post-market surveillance, adverse event reporting, and recall management. Learn why selecting the right agent is a vital strategic decision for ensuring long-term regulatory compliance in China. Key Questions: • What is an In-China Domestic Agent and why is it mandatory for medical device manufacturers? • Which key regulation defines the responsibilities of the agent? • How does the agent facilitate initial product registration and filing with the NMPA? • What are the agent's crucial duties regarding post-market surveillance and adverse event reporting? • Who is responsible for coordinating a product recall in China? • How does the agent act as a communication bridge between the manufacturer and Chinese authorities? • Why is the choice of an agent more than just an administrative step? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode demystifies the role of the Designated Marketing Authorization Holder (DMAH) for medical device companies entering Japan. We explore the critical differences between an MAH and a DMAH, outlining how the DMAH model allows foreign manufacturers to retain full ownership and control of their product approvals. Listeners will learn about the key responsibilities of a DMAH under the PMD Act, from regulatory submissions to post-market surveillance, and understand the strategic advantages of choosing an independent partner for long-term market success. Key Questions • What is a Designated Marketing Authorization Holder (DMAH) in Japan? • How does a DMAH differ from a standard Marketing Authorization Holder (MAH)? • Why can't foreign manufacturers register their medical devices directly with Japan's PMDA? • What are the core responsibilities of a DMAH for post-market surveillance? • How does appointing a DMAH give you more control over your product's registration? • What is a Foreign Restrictive Authorization Holder (FRAH) and how does it relate to the DMAH? • Should you appoint your distributor as your DMAH? • What are the risks of tying your market approval to a single commercial partner? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode delves into the essential role of the Australian Sponsor for medical device companies seeking to enter the Australian market. We explain the legal requirements set by the Therapeutic Goods Administration (TGA), the critical responsibilities of a sponsor, and analyze the significant strategic differences between appointing a distributor versus an independent third-party sponsor. Understand how this key decision impacts your regulatory approvals, market flexibility, and long-term success down under. • What is an Australian TGA Sponsor and why is it a legal necessity? • Who is legally responsible for your medical device once it's on the Australian market? • What are the key post-market surveillance duties of a sponsor? • Should you let your distributor act as your TGA Sponsor? • What are the major risks of tying your device registration to a commercial distributor? • How does an independent sponsor provide greater control over your market access? • What happens to your product registration if you decide to change your distributor? • Why is choosing the right sponsor a critical long-term business decision? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode demystifies the process of entering the New Zealand medical device market by focusing on the critical role of the New Zealand Sponsor, a mandatory requirement for all overseas manufacturers. We break down the sponsor's responsibilities as mandated by Medsafe, from the initial notification in the WAND database to the crucial ongoing duties of post-market surveillance and vigilance. This discussion highlights why the sponsor is more than just a local contact—they are your legal representative responsible for the device's lifecycle in the country. Key Questions: • What is a New Zealand Sponsor and why is one mandatory for foreign manufacturers? • How does Medsafe's WAND database system function for device notification? • What are the specific legal responsibilities a Sponsor undertakes? • What is the 30-day deadline for notifying a new medical device? • Beyond initial registration, what are the Sponsor's post-market obligations? • How quickly must a Sponsor update information if a device or manufacturer's details change? • What are the potential conflicts of interest when appointing a distributor as your Sponsor? • What evidence must a manufacturer have on file to support the Sponsor's declaration of conformity? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode demystifies Canada's dual-licensing system for medical devices. We clarify the critical differences between a product-specific Medical Device Licence (MDL) for Class II-IV devices and a company-specific Medical Device Establishment Licence (MDEL) required for Class I manufacturers, importers, and distributors. Learn who needs which license, the role of the importer, and why the concept of a regulatory correspondent is vital, even without a formal in-country representative requirement. • What is the difference between a Canadian MDL and an MDEL? • Which device classes require a product-specific Medical Device Licence? • Who is required to hold a Medical Device Establishment Licence? • As a foreign manufacturer, does my company need an MDEL to sell in Canada? • What role does the Canadian importer play in the regulatory process? • Does Canada require a formal in-country representative or authorized representative? • What are the annual renewal deadlines for each type of license? • What is the function of a regulatory correspondent? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode unpacks the essential requirements for placing medical devices on the Swiss market following the lapse of the EU-Switzerland Mutual Recognition Agreement. We explore the role and legal responsibilities of the mandatory Swiss Authorised Representative (CH REP), detail the past compliance deadlines for all device and IVD classes, and explain critical labeling and registration requirements with the Swiss authority, Swissmedic. Key Questions • Why is Switzerland now considered a 'third country' by the EU for medical devices? • What is a Swiss Authorised Representative (CH REP) and who is required to appoint one? • What are the specific legal responsibilities of a CH REP? • Have the compliance deadlines for appointing a CH REP for my device class already passed? • What specific information and symbols must be included on product labeling for the Swiss market? • What is the Swissdamed database and the CHRN registration number? • How does the Swiss regulatory framework differ from the EU MDR and IVDR? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode delves into the critical role of the European Authorised Representative (EC REP) for non-EU medical device and IVD manufacturers under the MDR and IVDR. We explore how the responsibilities have expanded beyond a simple administrative function to include significant legal liability and active compliance verification, making the choice of your EC REP a crucial strategic decision for successful market access. • What is a European Authorised Representative (EC REP)? • Why is appointing an EC REP mandatory for non-EU manufacturers? • How did the MDR and IVDR change the legal liability of the Authorised Representative? • What specific compliance documents must your EC REP verify before you can market your device? • Can your Authorised Representative be held responsible for your defective devices? • What is the relationship between an Authorised Representative and the Person Responsible for Regulatory Compliance (PRRC)? • How does the EC REP participate in post-market surveillance and incident reporting? • What should you look for when selecting an Authorised Representative for the EU market? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode breaks down the essential post-Brexit requirement for non-UK medical device manufacturers: the UK Responsible Person (UKRP). We explore the legal obligations, key responsibilities in relation to the MHRA, and the critical role the UKRP plays in registering devices, maintaining technical documentation, and facilitating post-market surveillance for access to the market in Great Britain. Key Questions: • What is a UK Responsible Person (UKRP) and why is it mandatory? • Which manufacturers are required to appoint a UKRP to access the market in Great Britain? • What are the primary legal duties and responsibilities of a UKRP? • How does the UKRP interact with the UK's regulatory body, the MHRA? • What specific documentation must the UKRP verify and maintain? • What are the crucial transition deadlines for CE marked devices before the UKCA mark becomes mandatory? • Why is selecting an independent UKRP, rather than a distributor, a strategic advantage? • How does the UKRP support post-market surveillance and vigilance activities? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode provides a comprehensive guide to the Brazil Registration Holder (BRH), a mandatory requirement for foreign medical device manufacturers seeking market access in Brazil. We explore the critical role the BRH plays as the legal holder of the ANVISA registration, detailing their extensive responsibilities from initial submission to post-market surveillance. The discussion emphasizes the strategic importance of choosing between a distributor and an independent third-party representative, highlighting the risks of commercial lock-in versus the flexibility and control offered by an independent partner. Key Questions • What is a Brazil Registration Holder (BRH) and why is it mandatory for ANVISA approval? • What are the legal responsibilities that a BRH assumes for a medical device? • What are the significant risks of appointing a distributor as your BRH? • How does an independent BRH give you more control over your Brazilian commercial strategy? • What key duties does the BRH perform, including B-GMP certification and vigilance reporting? • Which recent ANVISA regulations, like RDC 751/2022, define the current requirements? • Why is transferring a device registration to a new holder often a complex process? • How does the BRH model protect a manufacturer's intellectual property? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode breaks down the mandatory FDA requirement for foreign medical device manufacturers to appoint a U.S. Agent. We explore the specific roles, responsibilities, and qualifications of a U.S. Agent, clarifying their function as the essential communication link between your company and the FDA. Learn the key differences between a U.S. Agent and an Official Correspondent and understand the strategic considerations when choosing your representative to ensure smooth entry into the U.S. market. Key Questions: • What is the primary role of an FDA U.S. Agent? • Is appointing a U.S. Agent an optional or mandatory step for market entry? • Who is required to designate a U.S. Agent? • What are the specific responsibilities of a U.S. Agent during FDA interactions? • How does a U.S. Agent differ from an Official Correspondent? • What are the risks of appointing a distributor as your U.S. Agent? • What duties is a U.S. Agent *not* responsible for? • How is a U.S. Agent officially designated with the FDA? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode outlines a strategic framework for building powerful and mutually beneficial partnerships in the MedTech industry. We explore how to create a central hub for collaborators and tailor your value proposition to different partner types—from venture capitalists to distributors—all while adhering to core principles like transparency and long-term value. • How can you create a clear and effective partnership strategy? • What is the key to attracting the right type of partners for your MedTech company? • How should you tailor your value proposition for Venture Capital firms? • What do consulting firms look for in a MedTech partner? • How can you build a robust network of distributors and resellers? • What are the core principles that underpin any successful business partnership? • Is your company prepared to manage different types of strategic alliances simultaneously? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode provides a roadmap for medical device distributors and resellers looking to add a profitable, in-demand solution to their catalog. We explore the massive growth in the global medical device market, forecast for 2024 and beyond, and break down the key elements of a successful manufacturer-distributor partnership. Learn about the value proposition, from attractive margins to products that practically sell themselves, and discover the essential support systems, including sales training, a full suite of marketing resources, and dedicated channel management, that empower you to succeed. • What does the 2024 data say about the explosive growth of the medical device market? • How can you identify a medical device that will be a profitable addition to your portfolio? • What are the commercial benefits and margin structures you should look for in a partner? • How can a product's key differentiators make the sales process easier for your team? • What should a comprehensive partner program offer to guarantee your success? • Why is a dedicated channel manager crucial for your business development? • What kind of sales training and marketing resources should you expect from a manufacturer? • Are you ready to apply to become a distributor for a leading-edge solution? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

In this episode, we explore a powerful partnership model for MedTech consulting firms. Discover how collaborating with Pure Global can enhance your service offerings, help you deliver tangible, data-driven results for your clients, and unlock new revenue streams for your business. We detail the dedicated support, co-marketing opportunities, and sales collateral available to our partners, positioning you to drive unmatched client success in the complex world of global market access. Key Questions: • How can your consulting firm deliver even more value to your MedTech clients? • Are you looking for a best-in-class tool to enhance your current service offerings? • What if you could improve client ROI while reducing their time-to-market? • How can you create new, reliable revenue streams for your consultancy? • What does a dedicated partner support program for consultants look like? • Could co-branded marketing materials help you win more business? • Are you interested in co-marketing opportunities like joint webinars and whitepapers? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode is dedicated to venture capital firms invested in the medical device sector. We explore how a strategic regulatory partnership is not just an operational service but a critical tool for de-risking investments and accelerating the growth of portfolio companies. We discuss the tangible benefits of early regulatory planning, including faster market entry, enhanced capital efficiency, and a significant competitive advantage, ultimately amplifying the value of your MedTech portfolio. • How can VCs mitigate the significant risks posed by global regulatory hurdles? • What makes a regulatory partner a strategic asset rather than just a service provider? • How does early regulatory planning accelerate a MedTech startup's growth and path to profitability? • In what ways can a regulatory strategy provide a portfolio company with a sustainable competitive edge? • How can VCs leverage regulatory insights for more effective due diligence? • What exclusive benefits can portfolio companies gain from a dedicated partnership? • Is it possible to turn complex global regulations into a predictable advantage for your investments? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode unpacks the most common and costly documentation mistakes that medical device manufacturers make in their regulatory submissions. We explore specific gaps frequently flagged by Notified Bodies and the FDA, focusing on the Clinical Evaluation Report (CER), risk management files, and Post-Market Clinical Follow-up (PMCF) plans. Learn how to identify these deficiencies in your own technical files and, more importantly, how to fix them quickly to avoid delays and ensure a smoother path to market approval. • What are the most frequent deficiencies found in Clinical Evaluation Reports under the EU MDR? • How can you make your safety and performance objectives specific and measurable? • What does a truly comprehensive "State of the Art" section look like? • Are your equivalence claims strong enough to pass regulatory scrutiny? • Is your literature search protocol systematic and reproducible? • Why is a "living" risk management file essential for compliance? • Are you properly integrating post-market surveillance data into your technical documentation? • How do you write a justification for not conducting a PMCF study that regulators will accept? • What simple changes can you make to your documentation process to avoid common pitfalls? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

Choosing the right international standards is a critical strategic decision for any medical device manufacturer. This episode provides a clear framework for navigating the complex world of MedTech standards, starting with the foundational requirements for quality management (ISO 13485), risk management (ISO 14971), and software (IEC 62304). We explore how to build upon this core to select device-specific standards that ensure safety, efficacy, and smoother regulatory submissions worldwide, including the latest implications of the FDA's alignment with ISO 13485. Key Questions: • Which single standard forms the bedrock of a global medical device Quality Management System? • How will the FDA’s new rule, effective February 2, 2026, change quality system requirements in the US? • What is the required process for systematically identifying and controlling device risks for regulators? • If your device has software, which standard is absolutely essential for compliance? • Why is the ISO 10993 series on biocompatibility critical for ensuring patient safety? • How do you move beyond foundational standards to select ones specific to your device's technology, like sterilization or usability? • What are the strategic benefits of integrating standards compliance early in the design process? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode delves into the most common and costly mistakes medical technology companies make when seeking EU MDR compliance. We break down the complexities of technical documentation, clinical evidence requirements, risk management, and post-market surveillance, offering actionable strategies to avoid these pitfalls, streamline your submission process, and prevent significant delays and rejections from Notified Bodies. Key Questions: • Is your technical documentation truly 'reviewer-ready'? • Are you underestimating the new bar for clinical evidence under the MDR? • Does your risk management file accurately reflect your device's entire lifecycle? • Is your Post-Market Surveillance (PMS) plan proactive or just reactive? • How can you avoid the most common reasons for Notified Body pushback? • What makes a Clinical Evaluation Report (CER) robust enough for the MDR? • Are inconsistencies in your documentation putting your submission at risk? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode provides MedTech innovators with a foundational blueprint for embedding a global regulatory strategy into their product development process from the very beginning. We explore why a reactive, market-by-market approach fails and outline the critical early-stage decisions in market selection, quality management, and clinical evidence that pave the way for faster, more efficient international market access. Key Questions: • Why is a 'launch and learn' regulatory approach so risky for new devices? • How can early market selection influence your core product design? • What is the single most important standard to build your global strategy upon? • How do you design a clinical trial to satisfy multiple global regulators simultaneously? • What are the hidden costs of ignoring labeling and translation requirements until the last minute? • How has the EU MDR changed the game for clinical evidence worldwide? • When should you really start budgeting for global regulatory submissions? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode explores the critical, often mandatory, role of in-country representatives for medical device manufacturers entering foreign markets. We cover their functions from initial product registration and labeling to post-market vigilance and adverse event reporting. The episode also highlights the strategic pitfalls of using a distributor as a representative and the benefits of appointing an independent professional to maintain control and flexibility. • What is an in-country representative and why is it mandatory in most markets? • How does a local representative facilitate the product registration process? • What are their legal responsibilities for post-market surveillance and vigilance? • Why could appointing your distributor as your representative be a costly mistake? • How does an independent representative give you more control over your business? • What information must be included on the product labeling regarding the representative? • Who do national authorities contact if there is a safety issue with your device? • How can you switch distributors without having to re-register your product? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.